The global autoinjector devices market is projected to reach USD 1.7 billion in 2028 from USD 0.9 billion in 2023, growing at a CAGR of 14.0%. Whereas, the autoinjector finished formulations market is projected to reach USD 136.5 billion in 2028 from USD 59.6 billion in 2023, growing a CAGR of 18.0%. The key factors driving the growth of the global autoinjectors market are the growing availability of generic versions of autoinjectors, favorable government reimbursement scenario among others. However, the adoption of alternative modes of drug administration as injectable mode is often associated with needle phobia expected to restrain market growth to a certain extent.
The market for autoinjectors is consolidated, with key players strategizing to capture majority of the market. Prominent players in the market are Becton, Dickinson and Company (BD) (US), Ypsomed Holding AG (Switzerland), SHL Medical (Switzerland), West Pharmaceutical Services, Inc. (US), Recipharm AB (Sweden), Haselmeier GmbH (Germany), Owen Mumford Ltd. (UK), Gerreshiemer AG (Germany), Philip-Medisize, LLC (US), Oval Medical Technologies Ltd. (UK), Solteam Incorporation Co., Ltd. (China), Elcam Drug Delivery Devices (E3D) (Israel), Antares Pharma, Inc. (US), Jabil, Inc. (US), and the some of the major market players for finished formulations covered in this chapter include AbbVie Inc. (US), Amgen Inc. (US), Eli Lilly and Company (US), Novartis AG (Switzerland), Merck KGaA (Germany), Viatris Inc. (US), and Biogen (US).
To know about the assumptions considered for the study download the pdf brochure
Becton, Dickinson and Company (BD)
BD is the leading players in the global autoinjector devices market. The company offers self-injection device systems. BD is focused on strategies such as innovation, expansions, and partnerships to enhance its presence in the autoinjectors market. For instance, the company has successfully conducted human clinical trials for the BD Libertas wearable injector. The company’s strong geographic presence and technology-enabled solutions are contributing to its growing market share. BD faces increased competition from various autoinjector providers across the globe, including Ypsomed and SHL Medical. These companies pose a competitive threat in terms of product portfolio and brand recognition.
Ypsomed Holding AG
Ypsomed Holding AG is one of the leading players in the global autoinjector devices market. Ypsomed offers self-injection device systems along with infusion systems. The has a strong geographic presence along with patient-centric autoinjector products are contributing to its growing market share. Ypsomed is facing increased competition from various autoinjector providers across the globe, including BD and SHL Medical. These companies pose a competitive threat in terms of product portfolio and brand recognition.
AbbVie is one of the leading players in the Autoinjectors finished formulations market. The company’s blockbuster product is Humira Pen. AbbVie has a strong supply chain globally with wholesalers, distributors, government agencies, healthcare facilities, specialty pharmacies, and independent retailers marketing its products worldwide. The company has received a several regulatory approvals in the last three years for its finished formulations offered in autoinjector form. The company has a leading market position due to factors such as strong brand recognition, broad product portfolio, focus on innovation, and strong geographic presence.
Amgen focuses on discovery, development, manufacturing, and marketing of innovative human therapeutics. The company is engaged in the production of innovative medicines, expanding its global geographic reach, enhancing next-generation biomanufacturing, improving drug delivery systems, and offering branded biosimilars. The company offers autoinjector products for treatment of some of the chronic diseases including rheumatoid arthritis, cardiovascular disease, and inflammatory diseases.
Autoinjectors Market by Usage (Reusable, Disposable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Anaphylaxis), Route of administration (SC, IM), Volume (<3ml, >3ml), End User (Home Care, Hospitals) - Global Forecast to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE